Sandoz Expands Kundl Site Sterile Production
News Mar 12, 2013
Sandoz has officially opened its new facilities in Kundl, Austria, thereby expanding the production of sterile penicillins at the site significantly and creating 30 new jobs.
With the expansion, Kundl has added two new floors to its existing building and increased its powder facilities from 10 to 12 with a planned annual capacity of more than 150 million vials.
Approximately 190 million packs of medicinal products are distributed annually from the Kundl site to around 100 countries.
Kundl is Sandoz’s largest production site and one of the world's leading antibiotics manufacturers as well as the last remaining fully integrated penicillin producer in the western world. Currently 200 employees work in the sterile penicillins production.
The size of the two new floors is approximately 22,500 m³ which equates to about 22 single-family homes. Together with the current space of 26,300 m³, the site will be equivalent in size to 48 single-family homes.
Jeff George, Global Head of Sandoz, said: “Expanding our sterile production in Kundl demonstrates our focus on differentiated products and our commitment to Austria. The significant expansion of our sterile production will also play a major role in strengthening innovation at the Kundl site.”
"We have decided to expand our production of sterile penicillins due to strong worldwide demand for antibiotics. The additional lines increase security of supply for the market and allow us to respond quickly to changing needs in the fast-paced generics business.” said Ernst Meijnders, Chairman of the Executive Board of Sandoz GmbH in Austria.
The guests at the opening included local politicians, representatives from industry, Kundl village’s priest, Dr. Piotr Stachiewicz, as well as Tyrol’s Governor Günther Platter.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Nanoparticle Delivery of Curcumin Induces Tumor Cell DeathNews
Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cellsREAD MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE